BR9808523A - Peptìdeo antagonista de gnrh, composição farmacêutica para inibir a secreção de gonadotropinas em mamìferos, processos para o diagnóstico in vivo ou in vitro de uma condição onde gnrh está causando crescimento de tumor ou secreção hormonal em excesso e para inibir a secreção de gonadotropinas em mamìferos, e, intermediário para fazer um peptìdeo antagonista de gnrh. - Google Patents

Peptìdeo antagonista de gnrh, composição farmacêutica para inibir a secreção de gonadotropinas em mamìferos, processos para o diagnóstico in vivo ou in vitro de uma condição onde gnrh está causando crescimento de tumor ou secreção hormonal em excesso e para inibir a secreção de gonadotropinas em mamìferos, e, intermediário para fazer um peptìdeo antagonista de gnrh.

Info

Publication number
BR9808523A
BR9808523A BR9808523-9A BR9808523A BR9808523A BR 9808523 A BR9808523 A BR 9808523A BR 9808523 A BR9808523 A BR 9808523A BR 9808523 A BR9808523 A BR 9808523A
Authority
BR
Brazil
Prior art keywords
gnrh
mammals
secretion
antagonist peptide
condition
Prior art date
Application number
BR9808523-9A
Other languages
English (en)
Other versions
BR9808523B1 (pt
Inventor
Graeme Semple
Guangchen Jiang
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25273352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9808523(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of BR9808523A publication Critical patent/BR9808523A/pt
Publication of BR9808523B1 publication Critical patent/BR9808523B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/11—Gonadotropin; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"PEPTìDEO ANTAGONISTA DE GNRH, COMPOSIçãO FARMACêUTICA PARA INIBIR A SECREçãO DE GONADOTROPINAS EM MAMìFEROS, PROCESSOS PARA O DIAGNóSTICO IN VIVO OU IN VITRO DE UMA CONDIçãO ONDE GNRH ESTá CAUSANDO CRESCIMENTO DE TUMOR OU SECREçãO HORMONAL EM EXCESSO E PARA INIBIR A SECREçãO DE GONADOTROPINAS EM MAMìFEROS, E, INTERMEDIáRIO PARA FAZER UM PEPTìDEO ANTAGONISTA DE GNRH". Peptídeos são providos que tem melhorada duração de propriedades antagonísticas de GnRH. Estes antagonistas podem ser usados para regular a fertilidade e para tratar tumores dependentes de esteroídes, e para outras indicações de tratamento a curto prazo e longo prazo. Estes antagonistas tem um derivado de aminoPhe ou seu equivalente nas posições 5- ou 6-. Esse derivado é modificado de modo a conter um grupo carbamoíla ou heterociclo, incluindo uma porção de uréia em sua cadeia lateral. Os decapeptídeos particularmente efetivos, que continuam a demonstra supressão muito substancial de secreção LH em 96 horas após injeção, em a fórmula: Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph (L-hidroorotil)-D-4Aph (acetil)-Leu-Lys (isopropil)-Pro-D-Ala-NH~ 2~, e Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph (L-hidroorotil)-D-4Amf (Q~ 2~)-Leu-Lys (isopropil)-Pro-Xaa~ 10~, em que Q~ 2~é Cbm ou MeCbm e Xaa~ 10~ é D-Ala-NH~ 2~, D-Ala-ol ou Ala-ol.
BRPI9808523-9A 1997-04-11 1998-04-13 peptÍdeo antagonista de gnrh, composiÇço farmacÊutica para inibir a secreÇço de gonadotropinas em mamÍferos, e, intermediÁrio para fazer um peptÍdeo antagonista de gnrh. BR9808523B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/837,042 US5925730A (en) 1997-04-11 1997-04-11 GnRH antagonists
US08/837042 1997-04-11
PCT/US1998/007438 WO1998046634A1 (en) 1997-04-11 1998-04-13 GnRH ANTAGONISTS BEING MODIFIED IN POSITIONS 5 AND 6

Publications (2)

Publication Number Publication Date
BR9808523A true BR9808523A (pt) 2000-05-23
BR9808523B1 BR9808523B1 (pt) 2010-02-09

Family

ID=25273352

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9808523-9A BR9808523B1 (pt) 1997-04-11 1998-04-13 peptÍdeo antagonista de gnrh, composiÇço farmacÊutica para inibir a secreÇço de gonadotropinas em mamÍferos, e, intermediÁrio para fazer um peptÍdeo antagonista de gnrh.

Country Status (37)

Country Link
US (2) US5925730A (pt)
EP (1) EP1003774B1 (pt)
JP (2) JP4249806B2 (pt)
KR (1) KR100519421B1 (pt)
CN (1) CN1230442C (pt)
AR (1) AR011217A1 (pt)
AT (1) ATE319736T1 (pt)
AU (1) AU728642B2 (pt)
BR (1) BR9808523B1 (pt)
CA (1) CA2286190C (pt)
CY (2) CY1108063T1 (pt)
CZ (1) CZ299097B6 (pt)
DE (2) DE69833751T2 (pt)
DK (1) DK1003774T3 (pt)
EE (1) EE03974B1 (pt)
ES (1) ES2260833T3 (pt)
FR (1) FR09C0028I2 (pt)
HK (1) HK1025104A1 (pt)
HR (1) HRP980197B1 (pt)
HU (1) HU224836B1 (pt)
IL (1) IL132303A0 (pt)
LU (1) LU91585I2 (pt)
MY (1) MY114811A (pt)
NL (1) NL300395I2 (pt)
NO (2) NO324991B1 (pt)
NZ (1) NZ500142A (pt)
PL (1) PL194509B1 (pt)
PT (1) PT1003774E (pt)
RU (1) RU2199549C2 (pt)
SI (1) SI1003774T1 (pt)
SK (1) SK285381B6 (pt)
TR (1) TR199902956T2 (pt)
TW (1) TW505658B (pt)
UA (1) UA58547C2 (pt)
UY (1) UY24958A1 (pt)
WO (1) WO1998046634A1 (pt)
ZA (1) ZA983062B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5977302A (en) * 1997-11-20 1999-11-02 Ortho-Mcneil Pharmaceutical, Inc. Liquid phase process for the preparation of GnRH peptides
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
DE20321887U1 (de) 2003-11-10 2012-01-20 Allergan, Inc. Arzneimittel umfassend niedrige Dosierungen von Desmopressin
EP2322195A2 (en) 2003-11-10 2011-05-18 Reprise Biopharmaceutics, LLC Pharmaceutical compositions including low dosages of desmopressin
CN101037472B (zh) * 2006-03-14 2013-03-27 中国人民解放军军事医学科学院毒物药物研究所 具有低组胺释放作用的促黄体生成素释放激素拮抗剂
EP2526950A1 (en) * 2006-04-07 2012-11-28 Merrion Research III Limited Solid oral dosage form containing an enhancer
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
KR20110007614A (ko) * 2008-05-07 2011-01-24 메리온 리서치 Ⅲ 리미티드 ＧｎＲＨ 관련 화합물의 조성물 및 제조 방법
TWI480286B (zh) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
EP2421887B1 (en) * 2009-04-24 2015-04-22 Polypeptide Laboratories A/S Method for the manufacture of degarelix
CN102421414A (zh) * 2009-05-01 2012-04-18 辉凌公司 用于治疗前列腺癌的组合物
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (en) 2009-11-25 2011-06-03 Novetide, Ltd. Process for production of degarelix
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
US9260480B2 (en) 2010-10-27 2016-02-16 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
CA2822442C (en) 2010-12-22 2021-03-16 The Salk Institute For Biological Studies Cyclic crf antagonist peptides
CN103476419A (zh) 2011-01-07 2013-12-25 梅里翁第三研究有限公司 口服投药的含铁药物组合物
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013104745A1 (en) 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
EP2854831B1 (en) 2012-06-01 2024-07-10 Ferring B.V. Manufacture of degarelix
EP3250191B1 (en) 2015-01-29 2024-01-17 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
ES2885869T3 (es) * 2015-12-17 2021-12-15 Fresenius Kabi Ipsum S R L Procedimiento para la fabricación de degarelix y sus productos intermedios
CN107778355B (zh) * 2016-08-25 2021-04-20 成都圣诺生物制药有限公司 一种合成西曲瑞克的方法
WO2019110688A1 (en) 2017-12-05 2019-06-13 Ferring B.V. A composition comprising degarelix for use in the treatment of breast cancer
CN111943960B (zh) 2019-07-29 2022-02-15 广东东阳光药业有限公司 取代的嘧啶二酮类化合物及其用途
US11332495B2 (en) 2019-09-21 2022-05-17 RK Pharma Solutions LLC Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix
CN114456236A (zh) * 2020-11-09 2022-05-10 深圳市健翔生物制药有限公司 一种地加瑞克乙酰化杂质的制备方法
WO2023072284A1 (zh) 2021-11-01 2023-05-04 山东绿叶制药有限公司 促性腺素释放激素拮抗剂及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547370A (en) * 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
US4508921A (en) * 1984-06-28 1985-04-02 Merck & Co., Inc. Process for preparation of alpha-alkyl amino acids
US4866160A (en) * 1985-04-09 1989-09-12 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US5073624A (en) * 1985-04-09 1991-12-17 Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5296468A (en) * 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
DE593491T1 (de) * 1991-04-25 1994-11-17 Romano S.-Cergue Deghenghi LHRH-Antagonisten.
CA2136079A1 (en) * 1992-12-18 1994-07-07 Fortuna Haviv Lhrh antagonists having modified aminoacyl residues at positions 5 and 6
IL108509A0 (en) * 1993-02-22 1994-05-30 Salk Inst For Biological Studi GnRH antagonist peptides
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists

Also Published As

Publication number Publication date
JP4249806B2 (ja) 2009-04-08
US6214798B1 (en) 2001-04-10
NL300395I1 (nl) 2009-09-01
SK139699A3 (en) 2000-11-07
CZ358699A3 (cs) 2000-06-14
ES2260833T3 (es) 2006-11-01
MY114811A (en) 2003-01-31
CN1230442C (zh) 2005-12-07
AU728642B2 (en) 2001-01-11
SI1003774T1 (sl) 2006-08-31
EP1003774B1 (en) 2006-03-08
US5925730A (en) 1999-07-20
CA2286190C (en) 2007-01-09
CZ299097B6 (cs) 2008-04-23
KR20010006233A (ko) 2001-01-26
EE03974B1 (et) 2003-02-17
UA58547C2 (uk) 2003-08-15
DE122009000033I2 (de) 2011-07-21
NO2009016I2 (no) 2014-08-25
FR09C0028I2 (fr) 2010-06-11
JP2005120101A (ja) 2005-05-12
DK1003774T3 (da) 2006-07-03
CA2286190A1 (en) 1998-10-22
DE69833751T2 (de) 2006-11-09
ZA983062B (en) 1998-10-20
TW505658B (en) 2002-10-11
PL336213A1 (en) 2000-06-05
HK1025104A1 (en) 2000-11-03
RU2199549C2 (ru) 2003-02-27
WO1998046634A1 (en) 1998-10-22
FR09C0028I1 (pt) 2009-09-25
HUP0002704A2 (hu) 2000-12-28
CY2009008I1 (el) 2012-01-25
TR199902956T2 (xx) 2000-08-21
CY2009008I2 (el) 2012-01-25
BR9808523B1 (pt) 2010-02-09
HRP980197A2 (en) 1999-02-28
CY1108063T1 (el) 2012-01-25
HRP980197B1 (en) 2002-08-31
HUP0002704A3 (en) 2003-08-28
IL132303A0 (en) 2001-03-19
JP2001523229A (ja) 2001-11-20
NL300395I2 (nl) 2010-01-04
NO994906L (no) 1999-12-13
PL194509B1 (pl) 2007-06-29
HU224836B1 (en) 2006-03-28
JP3645255B1 (ja) 2005-05-11
CN1259959A (zh) 2000-07-12
DE69833751D1 (de) 2006-05-04
AR011217A1 (es) 2000-08-02
NZ500142A (en) 2001-10-26
UY24958A1 (es) 2001-03-16
EE9900479A (et) 2000-06-15
LU91585I2 (fr) 2009-09-17
NO2009016I1 (no) 2009-08-10
NO994906D0 (no) 1999-10-08
PT1003774E (pt) 2006-05-31
DE122009000033I1 (de) 2009-09-17
NO324991B1 (no) 2008-01-14
SK285381B6 (sk) 2006-12-07
AU6969898A (en) 1998-11-11
ATE319736T1 (de) 2006-03-15
EP1003774A1 (en) 2000-05-31
KR100519421B1 (ko) 2005-10-06

Similar Documents

Publication Publication Date Title
BR9808523A (pt) Peptìdeo antagonista de gnrh, composição farmacêutica para inibir a secreção de gonadotropinas em mamìferos, processos para o diagnóstico in vivo ou in vitro de uma condição onde gnrh está causando crescimento de tumor ou secreção hormonal em excesso e para inibir a secreção de gonadotropinas em mamìferos, e, intermediário para fazer um peptìdeo antagonista de gnrh.
CA1223198A (en) Repair of tissue in animals
US5003011A (en) Therapeutic decapeptides
DE69801369T2 (de) Peptidanaloge des lh-rh, ihre verwendungen und die sie enthaltenden pharmazeutischen zusammensetzungen
AU7117498A (en) Gnrh antagonists
KR890701117A (ko) 무시할 정도의 히스타민을 방출하는 루테인화 호르몬 방출 호르몬의 효과있는 길항체
KR890001572A (ko) 표유동물에게 히알우론산을 원격 투여하는 방법
KR950703999A (ko) 변성된 인슐린-유사 성장인자(modified insulin-like growth factors)
Breton et al. Neuropeptide Y stimulates in vivo gonadotropin secretion in teleost fish
MY139203A (en) Pharmaceutical composition
DE69731097D1 (de) Conotoxin peptid pviia
ATE71112T1 (de) Peptide, welche eine seitenkette aliphatischaromatischer ketone besitzen.
IE882091L (en) Pharmaceutical compositions comprising sometostatin¹analogues
Brown et al. Somatostatin-28, somatostatin-14 and somatostatin analogs: effects on thermoregulation
Holzer-Petsche et al. In vivo and in vitro actions of mammalian tachykinins
ATE73461T1 (de) Gnrh-antagonisten.
CO5140111A1 (es) Tratamiento de tumores mediante la administracion de compuestos que induce la liberacion de la hormona de crecimiento y sus antagonistas
Amoss et al. Stimulation of ovulation in the rabbit triggered by synthetic LRF
CA1338301C (en) Therapeutic octapeptide somatostatin analogs
ATE540968T1 (de) Alpha-fetoproteinpeptide und deren verwendungen
EP0225746A3 (en) Therapeutic decapeptides
Folkers et al. Decapeptides as effective agonists from L-amino acids biologically equivalent to the luteinizing hormone-releasing hormone.
Tuncel et al. The effect of vasoactive intestinal peptide (VIP) and inhibition of nitric oxide synthase on survival rate in rats exposed to endotoxin shock
Jin et al. The effect of bombesin-related peptides on the phagocytic function of mouse phagocytes in vitro
US5593965A (en) Anti-tumor effects of GnRH-III

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A E 11A ANUIDADES.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1994 DE 24/03/2009, ITEM 8.6, POR TER SIDO INDEVIDO.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/02/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 09.02.2020